Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antifungal isavuconazole under study for rare brain infection

NCT ID NCT04486885

Disease control Sponsor: Imagine Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Cerebral aspergillosis is a rare and serious brain infection caused by a mold. Doctors often use voriconazole as the first treatment, but a newer drug called isavuconazole may work as well with fewer side effects. This study looks back at the medical records of 41 children and adults in Europe who received isavuconazole for at least a week to see how many survived and whether the drug was safe. Researchers also measure drug levels in blood and spinal fluid to understand how the body handles it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
isavuconazole, an antifungal drug
What this could lead to
If isavuconazole works well, it could offer a better-tolerated treatment option for people with this rare brain infection.
What could go wrong
This is a small, retrospective study of 41 people, so it cannot prove cause and effect. The findings may not apply to all patients, and isavuconazole can cause side effects and drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

41 people

The number who actually took part.

Started

Aug 2021

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

40 adult ou pediatric patients, suffering frome cerebral aspergillosis, diagnosed between 2017 and 2020, and treated by isavuconazole at least 7 days

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria * In child or adult * Treated by isavuconazole at least 7 days * Diagnosed between March 2017 and June 2020 Exclusion Criteria: * Possible cerebral aspergillosis * isavuconazole treatment for less than 7 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral aspergillosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis neuroaspergillosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral aspergillosis Invasive aspergillosis

Contacts and locations

Locations

  • Hôpital Necker-Enfants Malades

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.